- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04141449
A Multilevel Intervention to Improve Timely Cancer Detection and Treatment Initiation (Potlako+)
A Multilevel Intervention (Potlako+) to Improve Timely Cancer Detection and Treatment
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The Potlako+ trial is a pair-matched, community-randomized study involving 20 rural and peri-urban communities in Botswana (population ~190,100 with ~100,000 30 years or older). Communities will be randomized 1:1 to the Potlako+ intervention versus standard care. The goal of the intervention is to identify individuals with symptoms/signs suggestive of cancer and expedite diagnosis (and treatment).
The trial includes a community education component focused on cancer awareness and importance of early diagnosis and a patient navigation component that aims to expedite the diagnostic evaluation. Community education will be directed at approximately 50,000 community residents (30 years and older). We anticipate approximately 1500 cancer suspects will be identified by their clinic providers.
Study Type
Enrollment (Estimated)
Phase
- Phase 2
Contacts and Locations
Study Contact
- Name: Kutlo Manyake, Dip Nursing
- Phone Number: +267-3902671
- Email: kmanyake@bhp.org.bw
Study Contact Backup
- Name: Mompati Mmalane, MD
- Email: mmmalane@bhp.org.bw
Study Locations
-
-
-
Gaborone, Botswana
- Recruiting
- Botswana Harvard AIDS Institute
-
Contact:
- Mompati Mmalane, MD
- Phone Number: +267-3902671
- Email: mmmalane@bhp.org
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Community members
Inclusion Criteria:
- Botswana citizen
- Age 30 years or older
- engaged in longitudinal care for chronic health problem
- resident of study community
Exclusion Criteria:
- Involuntary incarceration
- Educational messaging could interfere with clinical management or increase distress in the opinion or clinic or research staff
Cancer suspects
Inclusion Criteria:
- Botswana citizen
- Age 30 years or older
- resident of study community
- Recorded as a cancer suspect by clinic staff
Exclusion Criteria
- Involuntary incarceration
- Unable or unwilling to provide confirmation of informed consent
- Already engaged in oncology care
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Potlako intervention
|
Combined provider, patient, and health system intervention to expedite cancer diagnosis and care.
|
Active Comparator: Enhanced Care
|
Provider education and limited patient counseling.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Duration of combined Appraisal and Help-seeking intervals
Time Frame: Baseline
|
Number of days from patient symptom awareness to first clinic visit, among patients with moderate or high probability of cancer
|
Baseline
|
Duration of Diagnostic interval
Time Frame: From date of first clinic visit to date of cancer diagnosis or diagnosis excluding cancer, up to 365 days
|
Number of days from first clinic visit to cancer diagnosis or diagnosis excluding cancer, among patients with moderate or high probability of cancer
|
From date of first clinic visit to date of cancer diagnosis or diagnosis excluding cancer, up to 365 days
|
Duration of Pre-Treatment interval
Time Frame: From date of cancer diagnosis to date of cancer treatment up to 365 days
|
Number of days from cancer diagnosis to cancer treatment
|
From date of cancer diagnosis to date of cancer treatment up to 365 days
|
Proportion of patients treated with limited stage cancer
Time Frame: From date of cancer diagnosis to date of cancer treatment up to 365 days
|
Among patients with confirmed cancer, proportion treated with stage I/II disease
|
From date of cancer diagnosis to date of cancer treatment up to 365 days
|
Incidence of curative-intent treatment
Time Frame: From intervention start up to trial end at 1825 days
|
Cumulative incidence (cases per standardized population) of initiation of curative-intent cancer treatment
|
From intervention start up to trial end at 1825 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cancer presenting as emergency
Time Frame: From date of cancer diagnosis to date of cancer treatment up to 7 days
|
Among patients with confirmed cancer, proportion of cancer cases presenting as emergency (inpatient admission or death within 1 week of presentation with symptom).
|
From date of cancer diagnosis to date of cancer treatment up to 7 days
|
Incident low probability cancer syndromes
Time Frame: Baseline
|
Cumulative incidence (cases per standardized population) of presentation with low probability cancer syndromes
|
Baseline
|
Final diagnosis within 8 weeks
Time Frame: From date of first clinic visit to date of cancer diagnosis or diagnosis excluding cancer, up to 56 days
|
Among patients with moderate to high probability cancer symptoms, proportion with cancer diagnosis or exclusion of cancer diagnosis within 8 weeks of initial clinic visit
|
From date of first clinic visit to date of cancer diagnosis or diagnosis excluding cancer, up to 56 days
|
Incident invasive procedures in cancer suspects
Time Frame: From intervention start up to trial end at 1825 days
|
Cumulative incidence (cases per standardized population) of presentation with low, moderate, or high probability cancer syndromes
|
From intervention start up to trial end at 1825 days
|
Patients treated for cancer
Time Frame: From date of cancer diagnosis to date of cancer treatment up to 365 days
|
Among patients with confirmed cancer, proportion of cancer cases receiving any cancer-specific therapy
|
From date of cancer diagnosis to date of cancer treatment up to 365 days
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Scott Dryden-Peterson, MD, MSc, Brigham and Women's Hospital, Botswana Harvard AIDS Institute
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Digestive System Diseases
- Neoplasms
- Urogenital Neoplasms
- Neoplasms by Site
- Genital Neoplasms, Female
- Gastrointestinal Neoplasms
- Digestive System Neoplasms
- Gastrointestinal Diseases
- Intestinal Diseases
- Intestinal Neoplasms
- Rectal Diseases
- Colorectal Neoplasms
- Vulvar Diseases
- Rectal Neoplasms
- Anus Diseases
- Female Urogenital Diseases
- Female Urogenital Diseases and Pregnancy Complications
- Urogenital Diseases
- Genital Diseases
- Genital Diseases, Female
- Vulvar Neoplasms
- Anus Neoplasms
Other Study ID Numbers
- BHP0120
- R01CA236546 (U.S. NIH Grant/Contract)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
IPD Sharing Time Frame
IPD Sharing Access Criteria
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Neoplasms
-
GlaxoSmithKlineCompleted
-
Amphia HospitalRecruitingColonic Neoplasms MalignantNetherlands
-
John M. BuattiNational Cancer Institute (NCI); National Institutes of Health (NIH)CompletedUterine Cervical Neoplasms | Prostatic Neoplasms | Rectal Neoplasms | Endometrial Neoplasms | Anus NeoplasmsUnited States
-
Marquette General Health SystemUpper Michigan Brain Tumor CenterWithdrawnGlioma | MeningiomaUnited States
-
Ann & Robert H Lurie Children's Hospital of ChicagoCompletedBrain Stem Neoplasms, Primary | Neoplasms, Brain StemUnited States
-
GlaxoSmithKlineRecruitingNeoplasms, RectalUnited States, France, Italy, Japan, Spain, United Kingdom, Germany, Korea, Republic of, Canada, Netherlands
-
Russian Society of Colorectal SurgeonsRecruitingNeoplasms,ColorectalRussian Federation
-
Third Affiliated Hospital, Sun Yat-Sen UniversityRecruiting
-
Novartis PharmaceuticalsBayerCompletedColorectal Neoplasms | Rectal Neoplasms | Colonic NeoplasmsUnited States, Germany, Belgium, Canada, Spain, United Kingdom, Taiwan, France, Switzerland, Sweden, Portugal, New Zealand, Italy, Slovakia, Australia, Austria, Brazil, Hong Kong
Clinical Trials on Potlako intervention
-
Harvard School of Public Health (HSPH)Dana-Farber Cancer Institute; Brigham and Women's Hospital; Botswana Harvard... and other collaboratorsCompletedNeoplasms | HIV | Healthcare DisparityBotswana
-
Biolux Research Holdings, Inc.TerminatedOrthodontic Tooth MovementCanada
-
University of California, San FranciscoNational Cancer Institute (NCI)CompletedColorectal Carcinoma | Healthy Subject | Health Status UnknownUnited States
-
University of FloridaCompletedSensitivityUnited States
-
Roswell Park Cancer InstituteNational Cancer Institute (NCI); National Institute on Minority Health and...RecruitingHuman Papillomavirus InfectionUnited States
-
Ohio State University Comprehensive Cancer CenterCompleted
-
Mayo ClinicNational Cancer Institute (NCI)WithdrawnCancer Survivor | Peripheral Sensory Neuropathy
-
Nottingham Trent UniversityUnknownOverweight and ObesityUnited Kingdom
-
OHSU Knight Cancer InstituteOregon Health and Science UniversityRecruitingAnatomic Stage I Breast Cancer AJCC v8 | Anatomic Stage IA Breast Cancer AJCC v8 | Anatomic Stage IB Breast Cancer AJCC v8 | Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Prognostic... and other conditionsUnited States
-
Sidney Kimmel Cancer Center at Thomas Jefferson...American Cancer Society, Inc.Completed